

## **SUPPLEMENTAL MATERIAL**

**Table S1. Clinical characteristics and strain parameters, with reference value, of healthy controls**

|                          | Healthy controls (n=20) |                 |
|--------------------------|-------------------------|-----------------|
| Demographics             |                         |                 |
| Age (years)              | 41 ±12                  |                 |
| Sex                      | 15 (75%)                |                 |
| BMI (kg/m <sup>2</sup> ) | 25 ±4                   |                 |
| Strain parameter         |                         | Reference value |
| LV GLS                   | -23.43 ± 2.29           | -18.85          |
| LV GCS                   | -27.54 ± 3.25           | -20.04          |
| LV GRS                   | 71.19 ± 10.85           | 49.49           |
| RV GLS                   | -27.09 ± 4.22           | -18.65          |
| LA reservoir             | 39.70 ± 8.42            | 22.86           |
| LA booster               | 16.60 ± 3.81            | 8.98            |
| LA conduit               | 23.10 ± 6.64            | 9.82            |

Abbreviations: GCS = global circumferential strain, GLS = global longitudinal strain, GRS = global radial strain, LA = left atrial, LV = left ventricular, RV = right ventricular.

**Table S2. Common MACE predictors in acute myocarditis patients from literature**

| N=162                   | Clinical parameters + LV<br>GLS |                  | Clinical parameters + LV<br>GCS |                  | Clinical parameters + LV<br>GRS |                  | Clinical parameters + LA<br>reservoir strain |                  | Clinical parameters + LA<br>conduit strain |                  |
|-------------------------|---------------------------------|------------------|---------------------------------|------------------|---------------------------------|------------------|--|------------------|--|------------------|
|                         | HR (95% CI)                     | p-value          | HR (95% CI)                     | p-value          | HR (95% CI)                     | p-value          | HR (95% CI)                                  | p-value          | HR (95% CI)                                | p-value          |
| Age                     | 1.05 (1.02-1.07)                | <b>&lt;0.001</b> | 1.05 (1.03-1.08)                | <b>&lt;0.001</b> | 1.05 (1.02-1.07)                | <b>&lt;0.001</b> | 1.05 (1.03-1.08)                             | <b>&lt;0.001</b> | 1.05 (1.03-1.08)                           | <b>&lt;0.001</b> |
| Male sex                | 0.68 (0.32-1.47)                | 0.33             | 0.58 (0.26-1.29)                | 0.18             | 0.72 (0.32-1.61)                | 0.42             | 0.65 (0.30-1.40)                             | 0.27             | 0.65 (0.30-1.40)                           | 0.27             |
| LVEF (%)                | 1.02 (0.98-1.07)                | 0.36             | 1.07 (1.01-1.15)                | <b>0.04</b>      | 1.01 (0.97-1.05)                | 0.59             | 0.98 (0.96-1.00)                             | 0.10             | 0.98 (0.96-1.00)                           | 0.17             |
| LV GLS (%)              | 1.07 (1.01-1.14)<br><b>0.02</b> |                  | 1.17 (1.04-1.32)<br><b>0.01</b> |                  | 0.98 (0.96-0.99)<br><b>0.03</b> |                  | 0.99 (0.96-1.03)<br>0.73                     |                  | 1.01 (0.95-1.08)<br>0.66                   |                  |
| LV GCS (%)              |                                 |                  |                                 |                  |                                 |                  |  |                  |  |                  |
| LV GRS (%)              |                                 |                  |                                 |                  |                                 |                  |  |                  |  |                  |
| LA reservoir strain (%) |                                 |                  |                                 |                  |                                 |                  |  |                  |  |                  |
| LA conduit strain (%)   |                                 |                  |                                 |                  |                                 |                  |  |                  |  |                  |

Abbreviations: CI = confidence interval, EF = ejection fraction, GCS = global circumferential strain, GLS = global longitudinal strain, GRS = global radial strain, HR = hazard ratio, LA = left atrial, LV = left ventricular.

**Table S3. Overview of (suspected) etiologies of myocarditis**

| (suspected) Etiology of myocarditis                 | Frequency, n (%) |
|---|------------------|
| Viral   | 80 (49)          |
| Auto-immune disease                                 | 15 (9)           |
| Systemic lupus erythematosus                        | 6 (4)            |
| Systemic sclerosis                                  | 7 (4)            |
| Eosinophilic granulomatosis with polyangiitis       | 1 (0.6)          |
| Miller-Fisher syndrome                              | 1 (0.6)          |
| Giant-cell  | 1 (0.6)          |
| Eosinophilic  | 3 (2)            |
| Inflammatory presentation of genetic cardiomyopathy | 1 (0.6)          |
| Malaria   | 1 (0.6)          |
| Polymyositis  | 1 (0.6)          |
| Toxic after chemotherapy                            | 1 (0.6)          |
| Bacterial   | 4 (3)            |
| Unknown etiology                                    | 55 (34)          |

**Table S4. Overview of causes of death**

| <b>Cause of death</b>   | <b>Frequency, n (%)</b> |
|-------------------------|-------------------------|
| Sudden or cardiac death | 10 (59)                 |
| Cancer                  | 2 (12)                  |
| Auto-immune disease     | 4 (24)                  |
| Parkinson               | 1 (6)                   |

**Table S5. Clinical characteristics of four risk groups using age and LV GLS**

|                                       | Age < 40 years |              | Age ≥ 40 years |              | p-value     |
|---------------------------------------|----------------|--------------|----------------|--------------|-------------|
|                                       | Good LV GLS    | Worse LV GLS | Good LV GLS    | Worse LV GLS |             |
| <b>Demographics</b>                   |                |              |                |              |             |
| Age (years)                           | 27 ±7*         | 26 ±6*       | 53 ±10†        | 57 ±10†      | *0.59/†0.11 |
| Male                                  | 44 (86)        | 25 (83)      | 23 (76)        | 29 (57)      | <0.01       |
| BMI (kg/m <sup>2</sup> )              | 25 ±3          | 26 ±5        | 25 ±4          | 25 ±4        | NS          |
| <b>Medical history</b>                |                |              |                |              |             |
| Atrial fibrillation                   | 0              | 0            | 1 (3)          | 3 (6)        | NS          |
| Pericarditis                          | 2 2 (4)        | 0            | 0              | 3 (6)        | NS          |
| Myocarditis                           | 5 (10)         | 1 (3)        | 3 (10)         | 0            | NS          |
| Hypertension                          | 2 (4)          | 3 (10)       | 5 (16)         | 16 (31)      | 0.001       |
| Hypercholesterolemia                  | 3 (6)          | 0            | 3 (10)         | 8 (16)       | NS          |
| Chronic obstructive pulmonary disease | 1 (2)          | 0            | 3 (10)         | 3 (6)        | NS          |
| Diabetes Mellitus                     | 1 (2)          | 0            | 1 (3)          | 4 (8)        | NS          |
| Autoinflammatory disease              | 3 (5)          | 3 (10)       | 5 (16)         | 13 (25)      | <0.05       |
| <b>Clinical presentation</b>          |                |              |                |              |             |
| Chest pain                            | 45 (88)        | 23 (77)      | 24 (80)        | 31 (61)      | 0.01        |
| Dyspnoea                              | 16 (31)        | 8 (27)       | 10 (33)        | 22 (43)      | NS          |
| Collapse                              | 4 (8)          | 1 (3)        | 0              | 7 (14)       | NS          |
| Flulike symptoms                      | 36 (71)        | 21 (70)      | 14 (47)        | 27 (53)      | NS          |
| Fever                                 | 26 (51)        | 12 (40)      | 10 (33)        | 10 (20)      | <0.01       |
| Smoking status                        |                |              |                |              | NS          |
| Never                                 | 37 (73)        | 21 (70)      | 21 (70)        | 32 (63)      |             |
| Former smoker                         | 4 (8)          | 0            | 5 (17)         | 11 (22)      |             |
| Current smoker                        | 10 (20)        | 8 (27)       | 4 (13)         | 8 (16)       |             |
| Heart rate (bpm)                      | 80 ±23         | 98 ±26       | 80 ±22         | 92 ±33       | <0.01       |
| Systolic blood pressure (mmHg)        | 125 ±18        | 122 ±25      | 132 ±19        | 132 ±29      | NS          |
| Diastolic blood pressure (mmHg)       | 74 ±12         | 75 ±18       | 81 ±11         | 82 ±19       | 0.03        |
| Killip class                          |                |              |                |              | NS          |
| Class I                               | 49 (96)        | 26 (87)      | 27 (90)        | 39 (76)      |             |
| Class II                              | 1 (2)          | 2 (7)        | 2 (7)          | 10 (20)      |             |
| Class III                             | 0              | 0            | 1 (3)          | 0            |             |

| Class IV   | 1 (2)           | 2 (7)            | 0               | 2 (4)           |        |
|--|-----------------|------------------|-----------------|-----------------|--------|
| <b>Laboratory findings</b>                                       |                 |                  |                 |                 |        |
| Creatinine ( $\mu\text{mol/L}$ ) at admittance                   | 77 [69-83]      | 80 [70-108]      | 77 [69-91]      | 81 [67-95]      | NS     |
| Elevated troponin (%)  | 49 (98)         | 29 (100)         | 24 (90)         | 45 (92)         | NS     |
| Creatin kinase, maximum (U/L)                                    | 529 [363-975]   | 583 [382-1075]   | 257 [158-599]   | 161 [66-485]    | NS     |
| NTproBNP, maximum (pmol/L)                                       | 167 [36-392]    | 2226 [537-16650] | 199 [5-2650]    | 1500 [371-4418] | NS     |
| Leucocytes, maximum ( $10^9/\text{L}$ )                          | 10.6 [8.2-13.2] | 11.7 [7.8-14.7]  | 11.3 [7.5-15.7] | 10.6 [8.2-13.8] | NS     |
| C-reactive protein, maximum (mg/L)                               | 31 [16-88]      | 91 [27-187]      | 47 [8-126]      | 43 [9-96]       | 0.04   |
| <b>Electrocardiography</b>                                       |                 |                  |                 |                 |        |
| Conduction disorders   |                 |                  |                 |                 |        |
| High degree AV-block (2 <sup>nd</sup> or 3 <sup>rd</sup> degree) | 1 (2)           | 0                | 0               | 1 (2)           | NS     |
| Left bundle branch block   | 0               | 0                | 1 (3)           | 5 (10)          | NS     |
| Right bundle branch block  | 0               | 2 (7)            | 2 (7)           | 2 (4)           | NS     |
| ST-segment elevation   | 38 (76)         | 21 (75)          | 15 (50)         | 14 (24)         | <0.001 |
| ST-segment depression  | 10 (20)         | 11 (40)          | 4 (13)          | 13 (26)         | NS     |
| <b>Cardiac MRI</b>   |                 |                  |                 |                 |        |
| <i>Left ventricle</i>  |                 |                  |                 |                 |        |
| Ejection fraction (%)  | 58 $\pm$ 7      | 46 $\pm$ 11      | 59 $\pm$ 7      | 43 $\pm$ 14     | <0.001 |
| End-diastolic volume, indexed ( $\text{mL}/\text{m}^2$ )         | 91 $\pm$ 16     | 101 $\pm$ 24     | 85 $\pm$ 21     | 104 $\pm$ 42    | 0.02   |
| End-systolic volume, indexed ( $\text{mL}/\text{m}^2$ )          | 38 $\pm$ 9      | 57 $\pm$ 25      | 35 $\pm$ 13     | 62 $\pm$ 41     | <0.001 |
| Mass, indexed ( $\text{g}/\text{m}^2$ )                          | 62 $\pm$ 12     | 63 $\pm$ 18      | 57 $\pm$ 11     | 61 $\pm$ 18     | NS     |
| Cardiac output (L/min)   | 7.1 $\pm$ 1.7   | 6.6 $\pm$ 1.7    | 6.7 $\pm$ 1.9   | 5.8 $\pm$ 1.5   | <0.01  |
| <i>Right ventricle</i>   |                 |                  |                 |                 |        |
| Ejection fraction (%)  | 56 $\pm$ 5      | 49 $\pm$ 9       | 56 $\pm$ 4      | 51 $\pm$ 13     | 0.001  |
| End-diastolic volume, indexed ( $\text{mL}/\text{m}^2$ )         | 93 $\pm$ 15     | 86 $\pm$ 23      | 89 $\pm$ 21     | 76 $\pm$ 29     | <0.01  |
| End-systolic volume, indexed ( $\text{mL}/\text{m}^2$ )          | 41 $\pm$ 9      | 45 $\pm$ 16      | 39 $\pm$ 10     | 38 $\pm$ 21     | NS     |
| <b>Late gadolinium enhancement</b>                               |                 |                  |                 |                 |        |
| Present  | 47 (94)         | 27 (90)          | 27 (90)         | 42 (84)         | NS     |
| Quantification (% of LV mass)                                    | 6.3 [3.6-8.4]   | 7.2 [1.8-11.7]   | 3.6 [2.8-8.7]   | 3.9 [1.3-7.5]   | NS     |
| <b>T2 weighted imaging</b>                                       |                 |                  |                 |                 |        |
| Performed  | 50 (98)         | 28 (93)          | 30 (100)        | 49 (96)         | NS     |
| Myocardial oedema present  | 47 (94)         | 23 (82)          | 17 (57)         | 33 (49)         | <0.01  |
| <b>Admission</b>   |                 |                  |                 |                 |        |

|                                    |         |          |          |          |                 |  |
|------------------------------------|---------|----------|----------|----------|-----------------|--|
| Admission duration (days)          | 5 [4-8] | 6 [3-11] | 6 [3-12] | 9 [6-15] | NS              |  |
| Transfer to intensive care unit    | 4 (8)   | 6 (20)   | 2 (7)    | 6 (12)   | NS              |  |
| Start of immunosuppressive therapy | 4 (8)   | 5 (17)   | 5 (17)   | 9 (18)   | NS              |  |
| <b>Events</b>                      |         |          |          |          |                 |  |
| All-cause death                    | 2       | 1        | 3        | 12       | <b>&lt;0.01</b> |  |
| HF hospitalization                 | 0       | 1        | 1        | 5        | NS              |  |
| Life threatening arrhythmias       | 1       | 0        | 2        | 8        | <b>0.02</b>     |  |
| MACE ‡                             | 3       | 2        | 4        | 20       | <b>&lt;0.01</b> |  |

\* = good versus low GLS in patients with age <40 years, † = good versus low GLS in patients with age >40 years, ‡ When more than 1 event, the first event was included for the combined endpoint ‘MACE’.

NS = not significant.

Data is presented as mean ± standard deviation, median (interquartile range) or number (%).


Abbreviations: BMI = body mass index, MACE = major adverse cardiovascular events.

**Table S6. Inter- and intraobserver variability of strain parameters**

| Strain parameters                | Interobserver variability |         | Intraobserver variability |         |
|----------------------------------|---------------------------|---------|---------------------------|---------|
|                                  | ICC (95% CI)              | p-value | ICC (95% CI)              | p-value |
| Left ventricular GLS (%)         | 0.94 (0.86-0.98)          | <0.001  | 0.92 (0.82-0.97)          | <0.001  |
| Left ventricular GCS (%)         | 0.82 (0.61-0.93)          | <0.001  | 0.91 (0.80-0.97)          | <0.001  |
| Left ventricular GRS (%)         | 0.99 (0.97-1.00)          | <0.001  | 0.91 (0.79-0.97)          | <0.001  |
| Right ventricular GLS (%)        | 0.90 (0.76-0.96)          | <0.001  | 0.95 (0.88-0.98)          | <0.001  |
| Left atrial reservoir strain (%) | 0.97 (0.92-0.98)          | <0.001  | 0.90 (0.76-0.96)          | <0.001  |
| Left atrial conduit strain (%)   | 0.96 (0.89-0.98)          | <0.001  | 0.96 (0.89-0.98)          | <0.001  |
| Left atrial booster strain (%)   | 0.89 (0.75-0.96)          | <0.001  | 0.88 (0.73-0.95)          | <0.001  |

Abbreviations: GCS = global circumferential strain, GLS = global longitudinal strain, GRS = global radial strain


**Figure S1. Flowchart of the study population**



Suspected acute myocarditis patients who underwent CMR between 2005 and 2019 were retrospectively screened in four Dutch centers. Patients were included when they fulfilled the ESC position statement criteria including a diagnostic CMR criterium and had a maximum timeframe of 3 months between CMR and hospitalization. Patients were excluded if all cine images (short- and both long-axis) were unavailable for offline analysis, of insufficient quality or had no or too short follow-up. A total of 162 patients was included.

Abbreviations: CMR = cardiovascular magnetic resonance, ESC = European Society of Cardiology, FU = follow-up.

**Figure S2. Kaplan Meier survival analysis of phasic strain parameters and LGE %**



Abbreviations: GRS = global radial strain, LGE = late gadolinium enhancement, LV = left ventricular.

(A) LV-GRS is associated with event-free survival; (B) LGE extent is not associated with event-free survival